Mrs Donnet Andrea Riley, FNP | |
781 Palmer Rd Apt 3a, Bronxville, NY 10708-3309 | |
(772) 475-1348 | |
Not Available |
Full Name | Mrs Donnet Andrea Riley |
---|---|
Gender | Female |
Speciality | General Practice |
Location | 781 Palmer Rd Apt 3a, Bronxville, New York |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1821621301 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | F345155-01 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Donnet Andrea Riley, FNP 781 Palmer Rd Apt 3a, Bronxville, NY 10708-3309 Ph: (772) 475-1348 | Mrs Donnet Andrea Riley, FNP 781 Palmer Rd Apt 3a, Bronxville, NY 10708-3309 Ph: (772) 475-1348 |
News Archive
LodgeNet Healthcare today announced the expansion of their interactive patient television system at one of the country's leading cancer hospitals. In March of 2009, LodgeNet Healthcare and The University of Texas M. D. Anderson Cancer Center partnered on designing a state-of-the-art television system capable of delivering interactive services for patients including patient education and entertainment programming.
Scientists at VIB and KU Leuven have discovered a crucial factor in the spread of cancer. A team led by professor Massimiliano Mazzone has demonstrated that the metabolism of macrophages, a particular type of white blood cell, can be attuned to prevent the spread of cancer.
A genetic search that wound its way from patients to mouse models and back to patients has uncovered an unlikely gene critically involved in a common birth defect which causes mental retardation, motor delays and sometimes autism, providing a new mechanism and potentially improving treatment for the disorder.
Sumitomo Dainippon Pharma Co., Ltd. and SanBio Co., Ltd., acting through its U.S. subsidiary SanBio, Inc., announced on September 26 that the two companies have entered into a joint development and license agreement for exclusive marketing rights in the U.S. and Canada ("Agreement") for SB623, a cell therapy for the treatment of patients with chronic stroke discovered and currently under development by SanBio.
Certain routine demographic, clinical, and laboratory values can be used to identify advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).
› Verified 3 days ago